Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
Edwards Lifesciences Corporation logo

NASDAQ · EW

Edwards Lifesciences Corporation

Healthcare · Medical - Devices

$92.01

Down-$2.43 (-2.57%)

Updated Oct 31, 2026, 6:22 PM

SID Score

6.9/10

Composite research score

Smart Money

58/100

Neutral

Market cap
49.46B
P/E ratio
36.1
Dividend yield
0.00%
52-week range
$74.66 – $96.29
Volume
6.04M
Avg. volume
4.51M

Price performance · EW

EW price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

EW closed at $92.01 after 21 trading sessions, up 8.06% for the selected period.

Last close
$92.01
Period change
+8.06%
Period low
$84.24
Period high
$94.44
Daily close
View OHLC price history
EW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$94.55$95.34$91.87$92.016.04M
Oct 29, 2026$92.63$95.20$91.995$94.444.68M
Oct 28, 2026$89.98$92.12$89.9001$91.782.3M
Oct 27, 2026$90.19$91.33$89.7301$90.823.02M
Oct 26, 2026$89.07$90.7133$88.91$90.563.33M
Oct 23, 2026$90.11$91.05$88.97$89.073.1M
Oct 22, 2026$88.64$90.19$88.28$90.093.05M
Oct 21, 2026$87.52$89.32$87.06$88.402.72M
Oct 20, 2026$87.73$88.34$87.16$88.291.8M
Oct 19, 2026$86.66$87.73$86.55$87.222.76M
Oct 16, 2026$88.21$88.40$86.085$86.604.01M
Oct 15, 2026$86.62$88.41$85.54$88.104.68M
Oct 14, 2026$85.47$86.62$84.83$86.454.04M
Oct 13, 2026$86.55$86.77$85.07$85.273.64M
Oct 12, 2026$85.24$86.41$84.55$86.393.32M
Oct 9, 2026$84.60$85.34$83.22$85.213.89M
Oct 8, 2026$85.65$85.78$82.425$84.246.52M
Oct 7, 2026$86.65$87.30$85.49$85.783.51M
Oct 6, 2026$87.54$87.875$85.94$86.483.38M
Oct 5, 2026$85.635$87.57$85.34$87.233.32M
Oct 2, 2026$85.52$86.48$84.66$85.152.41M

Latest EW news

The latest Smart Investors Daily articles mentioning EW.

Stock researchCompany · Overview

EW research

Overview

Company profile and research snapshot.

Company profile

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$95.40
Implied upside
—
Analysts
17
EW recent ratings
DateFirmRatingTarget
Oct 7, 2026BarclaysOverweight—
Sep 11, 2026BTIGBuy—
Jul 24, 2026Leerink PartnersOutperform—
Jul 24, 2026Piper SandlerOverweight—
Jul 24, 2026JP MorganOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 23, 2026

Does Valve Repair Approval Change The Bull Case For Edwards Lifesciences (EW)?

Edwards Lifesciences reported past FDA approvals for its PASCAL Precision system for tricuspid valve repair and PASCAL Ace with Capture Clarity for degenerative mitral TEER, giving the business a broader U.S. transcatheter repair toolkit for patients who are not good candidates for open heart surgery. The combination of tricuspid and mitral TEER approvals makes Edwards Lifesciences the only supplier offering both repair and replacement transcatheter options across these valves in the U.S.,...

Yahoo · Oct 21, 2026

FDA Approval of Edwards Lifesciences’ PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve Disease

IRVINE, Calif., October 21, 2026--Edwards Lifesciences Corporation (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved its PASCAL Precision system for tricuspid valve repair. The system is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation (TR) despite optimal medical therapy who are deemed at intermediate or greater risk for surgery and deemed appropriate for transcatheter edge-to-edge tr

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By